Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 Shares of Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 9,000 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $99.64, for a total value of $896,760.00. Following the sale, the director owned 7,825 shares of the company’s stock, valued at approximately $779,683. This represents a 53.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Stock Performance

Shares of PTGX opened at $94.92 on Tuesday. Protagonist Therapeutics, Inc. has a twelve month low of $47.53 and a twelve month high of $107.84. The firm’s 50 day moving average price is $101.60 and its 200 day moving average price is $92.18. The firm has a market cap of $6.10 billion, a PE ratio of -52.44 and a beta of 1.89.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. On average, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 3.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PTGX. Weiss Ratings reissued a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. Wolfe Research initiated coverage on Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 target price on the stock. TD Cowen boosted their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Wall Street Zen raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Barclays raised their price objective on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research report on Thursday, March 19th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $115.21.

Institutional Trading of Protagonist Therapeutics

Several large investors have recently made changes to their positions in the business. Farther Finance Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after buying an additional 156 shares during the last quarter. Greenline Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the fourth quarter valued at approximately $27,000. EverSource Wealth Advisors LLC increased its stake in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after buying an additional 314 shares during the period. Abich Financial Wealth Management LLC bought a new stake in shares of Protagonist Therapeutics during the third quarter worth $62,000. Finally, Osaic Holdings Inc. boosted its holdings in Protagonist Therapeutics by 79.5% in the second quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock valued at $65,000 after acquiring an additional 525 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.